+86 16650237703
Author:Kangdi 14-08-2026
Audience: B2B procurement managers, sourcing directors, OTC brand owners, and import distributors evaluating pain patch OEM China factory direct sourcing vs trading company intermediaries.
Reading time: 13 minutes
What you'll get: 6 advantages of China factory direct sourcing, 5 trading company intermediary risks, 4 factory direct verification criteria, 5-step direct factory engagement SOP, and 5 FAQ including why Henan Kangdi operates as direct manufacturer.
1. 6 Advantages of China Factory Direct Sourcing
Direct sourcing from a China pain patch OEM factory (vs going through a trading company intermediary) offers 6 measurable advantages for B2B buyers in 2026.
Advantage 1 — Lower unit cost (15–30% saving)
Trading companies typically add 15–30% markup on top of factory FOB price to cover their commission, marketing, and customer service overhead. Direct factory engagement eliminates this markup. For example, a USD 0.10 FOB pain patch through a trading company becomes USD 0.115–0.130; direct factory engagement keeps it at USD 0.10 (plus your own sourcing overhead). For a 500,000-unit annual order, this saves USD 7,500–15,000 annually.
Advantage 2 — Direct formulation customization
Working directly with the factory's R&D team enables formulation customization: capsaicin concentration, menthol level, lidocaine combination, hydrogel matrix density, adhesive system, patch size, and packaging design. Trading companies typically offer limited customization (only standard SKUs); direct factory engagement unlocks the full formulation library and custom development.
Advantage 3 — Direct regulatory documentation access
Factory direct engagement provides direct access to FDA Facility Registration, EU MDR technical documentation, ISO 13485 certificate, Drug Master File (DMF), stability data, and clinical evaluation reports. Trading companies act as middlemen and may not have direct access to underlying documentation. For US / EU / GCC regulatory filings, direct documentation access accelerates timelines.
Advantage 4 — Faster communication and lead time
Direct factory communication eliminates the 24–48 hour delay from trading company relay. Factory direct engagement typically delivers quotation in 2–5 business days, sample dispatch in 7–10 days, and production lead time 25–35 days. Trading company engagement adds 5–10 days to each step.
Advantage 5 — Better quality control and traceability
Factory direct engagement enables direct quality control: batch sampling, in-process inspection, factory audit, and direct corrective action requests. Trading companies have limited visibility into production processes; quality issues must be relayed through the trading company, slowing resolution.
Advantage 6 — Long-term partnership and IP protection
Direct factory partnership enables long-term cooperation: formulation lock-in for your brand, NDA / quality agreement protection, joint R&D for new products, and capacity reservation for Q4 retail peak. Trading companies typically do not sign NDA or quality agreement with the underlying factory.
2. 5 Trading Company Intermediary Risks
Despite the convenience, working with a trading company intermediary carries 5 measurable risks.
Risk 1 — Hidden markup and price opacity
Trading companies often bundle multiple costs (factory FOB + trading commission + handling fee + currency conversion margin + bank fee) into a single "landed price" that obscures the actual factory FOB. Buyers have limited visibility into true factory cost, making price benchmarking difficult.
Risk 2 — Limited formulation customization
Trading companies typically offer 5–10 standard SKUs sourced from 1–2 factories. Custom formulation requests are forwarded to the factory, adding 15–30 days and limiting flexibility. If your target market requires unique capsaicin concentration or specific ingredient combination, trading company route may not support it.
Risk 3 — Documentation fragmentation
Trading companies may aggregate documentation from multiple factories, making it unclear which factory actually produced your batch. For regulatory audits or recall situations, this fragmentation creates compliance risk.
Risk 4 — Communication latency and accuracy loss
Multi-language, multi-timezone communication through a trading company introduces latency (24–48 hours per round-trip) and accuracy loss (translation issues, technical detail omissions). Critical quality or specification issues may not reach the factory promptly.
Risk 5 — Limited IP protection
Trading companies typically do not sign NDA with the underlying factory. Your formulation, brand design, and packaging may be visible to other trading company clients or replicated by the factory for other buyers. Direct factory engagement with NDA / quality agreement provides stronger IP protection.
3. 4 Factory Direct Verification Criteria
To verify a China pain patch OEM factory is genuinely direct manufacturer (vs trading company reselling), use these 4 criteria.
Criterion 1 — Factory ownership and self-operation
Request the factory's business license (showing factory name and address), land use right certificate, and ISO 13485 certificate (certificates are issued to specific legal entities, not trading companies). Verify the legal entity name matches the factory name on quotation, contract, and invoice. Cross-check the address on Google Maps / Baidu Maps satellite view to confirm a real factory building (not a residential / commercial office).
Criterion 2 — Production capacity and equipment
Request factory profile showing: cleanroom area, production line capacity (units per day), equipment list, employee headcount, and export volume. Verify production capacity matches your order volume. For pain patch OEM, expect minimum 50,000 units per day capacity, ISO 14644 Class 8 cleanroom, and 50+ employees.
Criterion 3 — Regulatory and quality certifications
Request current copies of: ISO 13485:2016 certificate, FDA Facility Registration, EU MDR certificate (if claiming EU MDR), CFDA / NMPA medical device manufacturing license, and Drug Master File (if claiming drug product). Verify certificates are current (within 3 years) and issued to the factory's legal entity name. Verify FDA Facility Registration on FDA's public database.
Criterion 4 — Reference customers and export track record
Request reference customer list (with permission to contact), export shipment records (customs declaration copies, bill of lading samples), and country distribution map. Verify the factory has experience exporting to your target market. For US / EU / GCC markets, request references in those specific regions.
4. 5-Step Direct Factory Engagement SOP
Step 1 — Define your sourcing requirements (week 1)
Document: target product type (capsicum / menthol / lidocaine / cooling / hydrogel / non-hydrogel), order volume, target market regulatory pathway, formulation customization needs, packaging design, budget range, and target delivery date. This becomes the basis for factory shortlisting.
Step 2 — Shortlist 6–10 factories (week 1–2)
Search Alibaba, GlobalSources, Made-in-China, Thomasnet. Filter for factories (not trading companies): look for "Manufacturer" badge, "Factory" badge, ISO 13485, FDA Facility Registration, 5+ years export experience. Cross-verify factory address and legal entity. Request company profile and FOB quotation.
Step 3 — Sample request and technical discussion (week 2–4)
Request samples from top 6–8 factories. Discuss formulation customization options directly with factory technical team (R&D manager, production manager). Evaluate samples on: adhesion, skin comfort, active ingredient efficacy, packaging quality, lead time, and communication responsiveness.
Step 4 — Documentation review and factory audit (week 4–6)
Request and review: ISO 13485 certificate, FDA Facility Registration, EU MDR documentation, NMPA license, quality manual, batch records sample, stability data, and reference customer list. Visit top 2–3 finalists (or commission third-party audit by SGS / Bureau Veritas / Intertek). Verify the factory is genuinely a manufacturer, not a trading company.
Step 5 — Pilot run and commercial production (week 6+)
Start with pilot run (10,000–50,000 units). Sign NDA / quality agreement / supply agreement directly with the factory legal entity. Verify: production lead time, batch quality consistency, packaging accuracy, shipping documentation, customs clearance support. Then scale up to commercial volume (typically 200,000+ units per SKU).
5. FAQ (5 Questions)
FAQ 1: How do I verify a China pain patch supplier is genuinely a factory and not a trading company?
Request the business license, ISO 13485 certificate, and FDA Facility Registration — these are issued to specific legal entities. Verify the legal entity name matches across documents and quotation. Cross-check the factory address on satellite view. Ask for production capacity, equipment list, and employee headcount — a genuine factory will have specific numbers; a trading company will give vague answers.
FAQ 2: What is the typical cost saving from going factory direct vs trading company?
15–30% saving on FOB unit cost, depending on order volume and product complexity. For a USD 0.10 FOB pain patch through a trading company, direct factory engagement typically reduces cost to USD 0.07–0.085. For a 500,000-unit annual order, this saves USD 7,500–15,000 annually.
FAQ 3: Is Henan Kangdi Medical Devices a factory or a trading company?
Henan Kangdi Medical Devices is a direct manufacturer (factory) established in 1989 in Henan, China. We operate our own production lines, R&D team, cleanroom, and export documentation. We hold ISO 13485:2016 certification, FDA Facility Registration, and NMPA medical device manufacturing license. Our legal entity name on certificates matches our quotation, contract, and invoice. Buyers are welcome to visit our factory or commission a third-party audit (SGS / Bureau Veritas / Intertek) to verify direct manufacturer status.
FAQ 4: Can I order from a China factory without visiting in person?
Yes, most B2B buyers engage China factories without visiting in person by using third-party audit (SGS / Bureau Veritas / Intertek), video factory tour, sample evaluation, and reference customer contact. For first-time engagement, a third-party audit is highly recommended to verify factory status, quality system, and production capacity. Henan Kangdi welcomes video factory tour and third-party audit.
FAQ 5: What is the typical MOQ for direct factory pain patch OEM?
For direct factory engagement, MOQ typically ranges from 10,000 to 50,000 units per SKU for first order, depending on factory and product complexity. For established direct factory relationships, MOQ can be lower (5,000–10,000 units) for repeat orders. Trading companies may advertise lower MOQ (1,000–5,000 units) but at higher per-unit cost.
6. Conclusion
China factory direct pain patch OEM sourcing offers 6 measurable advantages: lower unit cost (15–30% saving), direct formulation customization, direct regulatory documentation access, faster communication, better quality control, and long-term partnership with IP protection. Trading company intermediaries carry 5 risks: hidden markup, limited customization, documentation fragmentation, communication latency, and limited IP protection. Use the 4 verification criteria to confirm a supplier is genuinely a factory (not a trading company), and follow the 5-step engagement SOP for direct factory sourcing. For deeper analysis of pain patch OEM factory audit, see Pain Patch OEM Factory Audit Guide. For pain patch OEM cost structure, see Pain Patch OEM Cost & Pricing Guide. For pain patch OEM documentation, see Pain Patch OEM Compliance Documentation Guide.
If you would like to discuss pain patch OEM China factory direct sourcing, including formulation customization, regulatory pathway, cost structure, and direct engagement process, contact Henan Kangdi Medical Devices at kangdimedical@gmail.com or +86 155 1754 1011. We have supplied pain patches to B2B buyers in 60+ countries since 1989 and welcome serious buyers for pain patch OEM / factory direct / cost analysis discussions.
References
- ISO 13485:2016 — Medical devices quality management systems: https://www.iso.org/standard/59752.html
- FDA Facility Registration / Drug Establishment Registration: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishment-registration
- EU MDR 2017/745 — Medical Device Regulation: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745
- China NMPA — Medical device manufacturing license: https://www.nmpa.gov.cn/
- Third-party audit firms (SGS, Bureau Veritas, Intertek): https://www.sgs.com/ / https://www.bureauveritas.com/ / https://www.intertek.com/
- Alibaba pain patch OEM sourcing: https://www.alibaba.com/
- GlobalSources pain patch OEM sourcing: https://www.globalsources.com/
- Made-in-China pain patch OEM sourcing: https://www.made-in-china.com/
- Thomasnet pain patch OEM sourcing: https://www.thomasnet.com/
- PubChem — Capsaicin: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin
- PubChem — Menthol: https://pubchem.ncbi.nlm.nih.gov/compound/Menthol
- PubChem — Lidocaine: https://pubchem.ncbi.nlm.nih.gov/compound/Lidocaine
- China Customs HS code 3004.90 — Transdermal patches: https://www.chinacustoms.gov.cn/
- China General Administration of Customs — Foreign Trade: http://english.customs.gov.cn/
- Incoterms 2020 — FOB / CIF / DAP: https://iccwbo.org/business-solutions/incoterms-rules/incoterms-2020/
Contact: For OEM/ODM inquiries, email kangdimedical@gmail.com or call +86 155 1754 1011.Updated: August 2026. Information current as of publication date. Sourcing strategies, regulatory frameworks, and supplier qualification criteria evolve continuously. Always verify current factory status with up-to-date documentation review, independent third-party audit, and reference checks before finalizing sourcing decisions.